Posts published in “Psilocybin”

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Psilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. This open-label study…

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption

Psychedelic Drug Legislative Reform and Legalization in the US

Psilocybin in Treatment-Resistant Depression

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis

Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Body mass index (BMI) does not predict responses to psilocybin

Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice

The pharmacology of psilocybin

The crystal structure of baeocystin

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial

Classic Psychedelics and Human-Animal Relations

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity

Natural language signatures of psilocybin microdosing

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis

Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats

Identification of ω-N-Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybe Natural Product

Production and extraction of psilocybin and psilocin from Psilocybe spp. mushrooms

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism